SCHEMBL3375367

SCHEMBL3375367

COc1ccc2c(Cl)cnnc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP2C19 P33261 3/20 0.42
PDE4A P27815 5/20 0.41
PDE4B Q07343 5/20 0.41
PDE4C Q08493 5/20 0.41
PDE4D Q08499 5/20 0.41
CYP2C9 P11712 1/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
NQO2 P16083 1/20 0.41
RAB9A P51151 1/20 0.41
PDE10A Q9Y233 1/20 0.40
EGFR P00533 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6098200 0.98 CYP3A4 (0.41) CYP1A2CYP3A4CYP2C19PDE4APDE4B
SCHEMBL1663396 0.86 CNR1 (0.43) CYP1A2PDE4APDE4BPDE4CPDE4D
SCHEMBL6099526 0.82 KDR (0.44) CYP1A2CYP3A4CYP2C19KDM4EPDE10A
SCHEMBL8148292 0.81 ALDH1A1 (0.49) CYP1A2CYP3A4CYP2C19ALDH1A1KDM4E
SCHEMBL24010094 0.81 ALDH1A1 (0.44) CYP1A2CYP2C19ALDH1A1KDM4EKMT2A
SCHEMBL1666537 0.79 TLR8 (0.43) CYP1A2CYP3A4ALDH1A1KDM4EKMT2A
SCHEMBL29589363 0.79 TLR8 (0.43) CYP1A2CYP3A4ALDH1A1KDM4EKMT2A
SCHEMBL24391836 0.78 HTR1A (0.41) ALDH1A1KDM4EKMT2ASMN1; SMN2MEN1
SCHEMBL8145610 0.78 ALDH1A1 (0.40) CYP1A2CYP3A4CYP2C19ALDH1A1KDM4E
SCHEMBL11195844 0.77 ALDH1A1 (0.52) CYP1A2CYP3A4ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022135-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF 1CBIO INC (US) 2026-01-22 US disclosed
US-12325720-B2 Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof 1CBIO, INC. (US) 2025-06-10 US disclosed
US-20240352046-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF 1CBIO INC (US) 2024-10-24 US disclosed
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
CN-116848091-A Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP 1) and uses thereof 1CBIO公司 2023-10-03 CN disclosed
EP-4236928-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF 1Cbio, Inc. (US) 2023-09-06 EP disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 US disclosed
US-20220135598-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2022-05-05 US disclosed
US-20220135598-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2022-05-05 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
US-7087602-B2 Cinnoline derivatives and use as medicine ASTRAZENECA UK LIMITED (GB) 2006-08-08 US disclosed
EP-0888310-B1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ASTRAZENECA AB (SE) 2005-09-07 EP disclosed
US-20030199513-A1 Cinnoline derivatives and use as medicine ZENECA LIMITED 2003-10-23 US disclosed
US-6514971-B1 For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans ZENECA LIMITED (GB) 2003-02-04 US disclosed
EP-0888310-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1999-01-07 EP disclosed
WO-1997034876-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199513-A1 Cinnoline derivatives and use as medicine VEGFA, CNR1, CCR7 CYP1A2 758/4885CYP3A4 1328/4885CYP2C19 1152/4885
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 CYP1A2 2884/4885CYP3A4 3752/4885CYP2C19 3078/4885
US-20260022135-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, NCEH1 CYP1A2 792/4885CYP3A4 2626/4885CYP2C19 2071/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 CYP1A2 2884/4885CYP3A4 3752/4885CYP2C19 3078/4885
US-20240352046-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, ENPP2 CYP1A2 1009/4885CYP3A4 2491/4885CYP2C19 914/4885
US-20220135598-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, ENPP2 CYP1A2 1009/4885CYP3A4 2491/4885CYP2C19 914/4885
US-12325720-B2 Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof ENPP1, ENPP3, ENPP2 CYP1A2 1009/4885CYP3A4 2491/4885CYP2C19 914/4885
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 CYP1A2 3826/4885CYP3A4 1770/4885CYP2C19 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.